129716-11-6

Basic information

• Product Name: 4-CHLORO-2-METHYLBENZYL ALCOHOL 97
• Synonyms: 4-CHLORO-2-METHYLBENZYL ALCOHOL 97;2-Methyl-4-chlorobenzyl alcohol
• CAS NO: 129716-11-6
• Molecular Formula: C₈H₉ClO
• Molecular Weight: 156.611
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Alcohols;C7 to C8;Oxygen Compounds
• Mol File: 129716-11-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 60-64 °C(lit.)
• Boiling Point: 258.8 °C at 760 mmHg
• Flash Point: 110.3 °C
• Appearance: /
• Density: 1.191g/cm³
• Vapor Pressure: 0.00686mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-CHLORO-2-METHYLBENZYL ALCOHOL 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-METHYLBENZYL ALCOHOL 97(129716-11-6)
• EPA Substance Registry System: 4-CHLORO-2-METHYLBENZYL ALCOHOL 97(129716-11-6)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 129716-11-6(Hazardous Substances Data)

Usage

General Description

4-CHLORO-2-METHYLBENZYL ALCOHOL 97 is a chemical compound with the molecular formula C8H9ClO. It is a colorless to pale yellow liquid with a mild, pleasant odor. This chemical is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a fragrance ingredient in the production of perfumes and cosmetics. 4-CHLORO-2-METHYLBENZYL ALCOHOL 97 is considered to be a high-purity grade, typically containing 97% or more of the active ingredient. It is important to handle this chemical with caution, as it may cause skin and eye irritation, and it should be stored in a cool, well-ventilated area away from heat and open flames.

InChI:InChI=1/C8H9ClO/c1-6-4-8(9)3-2-7(6)5-10/h2-4,10H,5H2,1H3

Upstream product

• 7499-07-2 4-chloro-2-methylbenzoic acid 
• 40137-29-9 2-methyl-4-chlorobenzaldehyde 
• 615-60-1 4-chloro-1,2-dimethylbenzene 
• 15393-58-5 4-chloro-2-methyl-benzoic acid ethyl ester 

Downstream Products

• 122488-73-7 1-(bromomethyl)-4-chloro-2-methylbenzene 
• 7499-07-2 4-chloro-2-methylbenzoic acid 
• 16470-10-3 (4-Chloro-2-methylphenyl)acetonitrile 
• 1034694-63-7 2-(4-chloro-2-methylphenyl)-3-hydroxypropanenitrile 
• 1613412-67-1 2-[5-[(4-chloro-2-methylphenyl)methoxy]pyrazol-1-yl]pyridine-4-carbonitrile 
• 947615-09-0 2-(benzhydrylidene-amino)-3-(4-chloro-2-methyl-phenyl)-propionic acid ethyl ester 
• 16470-09-0 2-methyl-4-chlorobenzyl chloride 
• 122488-74-8 6-Chloro-9-(4-chloro-2-methyl-benzyl)-2-trifluoromethyl-9H-purine 
• 27917-11-9 (4-chloro-2-methylphenyl)methanamine 
• 900505-19-3 4-(4-chloro-2-methyl-benzyl)-3-(4-chloro-phenyl)-7-iodo-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 
• 900505-06-8 2-(4-chloro-2-methyl-benzyl)-isoindole-1,3-dione 

Relevant articles and documents

LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT

Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

The disruption of the p53-Hdm2 protein-protein interaction induces cell growth arrest and apoptosis. We have identified the 1,4-benzodiazepine-2,5-dione scaffold as a suitable template for inhibiting this interaction by binding to the Hdm2 protein. Several compounds have been made with improved potency, solubility, and cell-based activities.

AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.